Impact of hepatitis B virus on clinicopathological features and outcomes after resection for pancreatic adenocarcinoma

Anticancer Research

Volumn 35, Issue 9, 2015, Pages 5123-5128

  Dumitrascu, Traian ^a   Pineau, Pascal ^b   Dima, Simona ^a   Stroescu, Cezar ^a   Brasoveanu, Vladislav ^a   Herlea, Vlad ^a   Ionescu, Mihnea ^a   Popescu, Irinel ^a  

^a FUNDENI CLINICAL INSTITUTE   (Romania)

^b INSTITUT PASTEUR   (France)

Author keywords

Hepatitis B virus; Pancreatectomy; Pancreatic adenocarcinoma

Indexed keywords

ADULT; AGED; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER SURGERY; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; POST TREATMENT SURVIVAL; PRIORITY JOURNAL; TREATMENT OUTCOME; ADENOCARCINOMA; COMPLICATION; DEMOGRAPHY; KAPLAN MEIER METHOD; MIDDLE AGED; PANCREATIC NEOPLASMS; PATHOLOGY; PHYSIOLOGY; POSTOPERATIVE CARE; VERY ELDERLY; VIROLOGY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; DEMOGRAPHY; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; POSTOPERATIVE CARE; TREATMENT OUTCOME;

EID: 84939633114     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (48)

1. Ma J and Jemal A: The rise and fall of cancer mortality in the USA: why does pancreatic cancer not follow the trend? Future Oncol 9: 917-9, 2013.
2. Malvezzi M, Bertuccio P, Levi F, La Vecchia C and Negri E: European cancer mortality predictions for the year 2014. Ann Oncol 25: 1650-6, 2014.
3. Hartwig W, Werner J, Jager D, Debus J and Buchler MW: Improvement of surgical results for pancreatic cancer. Lancet Oncol 14: e476-e485, 2013.
4. Liao WC, Chien KL, Lin YL, Wu MS, Lin JT, Wang HP and Tu YK: Adjuvant treatments for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis. Lancet Oncol 14: 1095-103, 2013.
5. Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, Niedergethmann M, Zulke K, Fahlke J, Arning MB, Sinn M, Hinke A and Riess H: Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA 310: 1473-81, 2013.
6. Lewis R, Drebin JA, Callery MP, Fraker D, Kent TS, Gates J and Vollmer CM Jr: A contemporary analysis of survival for resected pancreatic ductal adenocarcinoma. HPB (Oxford) 15: 49-60, 2013.
7. Nardone A, Anastassopoulou CG, Theeten H, Kriz B, Davidkin I, Thierfelder W, O'Flanagan D, Bruzzone B, Mossong J, Boot HJ, Butur D, Slaciková M, Panait ML, Hellenbrand W, DE Melker H, Sobotová Z, Icardi G, Andrews N, Pebody RG, VAN Damme P, Kafatos G, Miller E and Hatzakis A: A comparison of hepatitis B seroepidemiology in ten European countries. Epidemiol Infect 137: 961-9, 2009.
8. Tanase AM, Marchio A, Dumitrascu T, Dima S, Herlea V, Oprisan G, Dejean A, Popescu I and Pineau P: Mutation spectrum of hepatocellular carcinoma from eastern-European patients betrays the impact of a complex exposome. J Expo Sci Environ Epidemiol 25: 256-63, 2015.
9. Tanase AM, Dumitrascu T, Dima S, Grigorie R, Marchio A, Pineau P and Popescu I: Influence of hepatitis viruses on clinicopathological profiles and long-term outcome in patients undergoing surgery for hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 13: 162-72, 2014.
10. Zhou Y, Si X, Wu L, Su X, Li B and Zhang Z: Influence of viral hepatitis status on prognosis in patients undergoing hepatic resection for hepatocellular carcinoma: a meta-analysis of observational studies. World J Surg Oncol 9: 108-17, 2011.
11. Hassan MM, Li D, El-Deeb AS, Wolff RA, Bondy ML, Davila M and Abbruzzese JL: Association between hepatitis B virus and pancreatic cancer. J Clin Oncol 26: 4557-62, 2008.
12. Li L, Wu B, Yang LB, Yin GC and Liu JY: Chronic hepatitis B virus infection and risk of pancreatic cancer: a meta-analysis. Asian Pac J Cancer Prev 14: 275-9, 2013.
13. Luo G, Hao NB, Hu CJ, Yong X, Lu MH, Cheng BJ, Zhang Y and Yang SM: HBV infection increases the risk of pancreatic cancer: a meta-analysis. Cancer Causes Control 24: 529-37, 2013.
14. Majumder S, Bockorny B, Baker WL and Dasanu CA: Association between HBsAg positivity and pancreatic cancer: a meta-analysis. J Gastrointest Cancer 45: 347-52, 2014.
15. Xing S, Li ZW, Tian YF, Zhang LM, Li MQ and Zhou P: Chronic hepatitis virus infection increases the risk of pancreatic cancer: a meta-analysis. Hepatobiliary Pancreat Dis Int 12: 575-83, 2013.
16. Xu JH, Fu JJ, Wang XL, Zhu JY, Ye XH and Chen SD: Hepatitis B or C viral infection and risk of pancreatic cancer: a meta-analysis of observational studies. World J Gastroenterol 19: 4234-41, 2013.
17. Jin Y, Gao H, Chen H, Wang J, Chen M, Li G, Wang L, Gu J and Tu H: Identification and impact of hepatitis B virus DNA and antigens in pancreatic cancer tissues and adjacent noncancerous tissues. Cancer Lett 335: 447-54, 2013.
18. Wang DS, Wang ZQ, Zhang L, Qiu MZ, Luo HY, Ren C, Zhang DS, Wang FH, Li YH and Xu RH:. Are risk factors associated with outcomes in pancreatic cancer? PLoS One 7: e41984, 2012.
19. Wei XL, Qiu MZ, Chen WW, Jin Y, Ren C, Wang F, Luo HY, Wang ZQ, Zhang DS, Wang FH, Li YH and Xu RH: The status of HBV infection influences metastatic pattern and survival in Chinese patients with pancreatic cancer. J Transl Med 11: 249-58, 2013.
20. Gheorghe L, Csiki IE, Iacob S and Gheorghe C: The prevalence and risk factors of hepatitis B virus infection in an adult population in Romania: a nationwide survey. Eur J Gastroenterol Hepatol 25: 56-64, 2013.
21. Voiculescu M, Iliescu L, Ionescu C, Micu L, Ismail G, Zilisteanu D, Radasan A, Micu G and Pertache I: A cross-sectional epidemiological study of HBV, HCV, HDV and HEV prevalence in the SubCarpathian and South-Eastern regions of Romania. J Gastrointestin Liver Dis 19: 43-8, 2010.
22. Gheorghe L, Csiki IE, Iacob S, Gheorghe C, Smira G and Regep L: The prevalence and risk factors of hepatitis C virus infection in adult population in Romania: a nationwide survey 2. J Gastrointestin Liver Dis 19: 373-9, 2010.
23. Pitigoi D, Rafila A, Pistol A, Arama V, Molagic V and Streinu-Cercel A: Trends in hepatitis B incidence in Romania, 1989-2005. Euro Surveill 13: 8012-16, 2008.
24. Lin J, Wu JF, Zhang Q, Zhang HW and Cao GW: Virus-related liver cirrhosis: molecular basis and therapeutic options. World J Gastroenterol 20: 6457-69, 2014.
25. El Nakeeb A, Sultan AM, Salah T, El Hemaly M, Hamdy E, Salem A, Moneer A, Said R, Abu Eleneen A, Abu Zeid M, Abdallah T and Abdel Wahab M: Impact of cirrhosis on surgical outcome after pancreaticoduodenectomy. World J Gastroenterol 19: 7129-37, 2013.
26. Warnick P, Mai I, Klein F, Andreou A, Bahra M, Neuhaus P and Glanemann M: Safety of pancreatic surgery in patients with simultaneous liver cirrhosis: a single center experience. Pancreatology 11: 24-9, 2011.
27. Dejean A, Lugassy C, Zafrani S, Tiollais P and Brechot C: Detection of hepatitis B virus DNA in pancreas, kidney and skin of two human carriers of the virus. J Gen Virol 65: 651-5, 1984.
28. Hoefs JC, Renner IG, Askhcavai M and Redeker AG: Hepatitis B surface antigen in pancreatic and biliary secretions. Gastroenterology 79: 191-4, 1980.
29. Cavallari A, Vivarelli M, D'Errico A, Bellusci R, Scarani P, DeRaffaele E, Nardo B and Gozzetti G: Fatal necrotizing pancreatitis caused by hepatitis B virus infection in a liver transplant recipient. J Hepatol 22: 685-90, 1995.
30. Hohenberger P: Detection of HBs-Ag in the pancreas in cases of pancreatic carcinoma. Hepatogastroenterology 31: 239-41, 1984.
31. Hohenberger P: The pancreas as target organ for hepatitis B virus-immunohistological detection of HBsAg in pancreatic carcinoma and chronic pancreatitis. Leber Magen Darm 15: 58-63, 1985. (in German)
32. Shimoda T, Shikata T, Karasawa T, Tsukagoshi S, Yoshimura M and Sakurai I: Light microscopic localization of hepatitis B virus antigens in the human pancreas. Possibility of multiplication of hepatitis B virus in the human pancreas. Gastroenterology 81: 998-1005, 1981.
33. Yoshimura M, Sakurai I, Shimoda T, Abe K, Okano T and Shikata T: Detection of HBsAg in the pancreas. Acta Pathol Jpn 31: 711-7, 1981.
34. Shubina ME and Tsekhanovich KB: The pancreatic lesions in chronic viral hepatitis B. Eksp Klin Gastroenterol 6: 30-4, 2007. (in Russian)
35. El-Serag HB, Engels EA, Landgren O, Chiao E, Henderson L, Amaratunge HC and Giordano TP: Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A populationbased study of U.S. veterans. Hepatology 49: 116-23, 2009.
36. Huang J, Magnusson M, Torner A, Ye W and Duberg AS: Risk of pancreatic cancer among individuals with hepatitis C or hepatitis B virus infection: a nationwide study in Sweden. Br J Cancer 109: 2917-23, 2013.
37. Wang Y, Yang S, Song F, Cao S, Yin X, Xie J, Tu X, Xu J, Xu X, Dong X and Lu Z: Hepatitis B virus status and the risk of pancreatic cancer: a meta-analysis. Eur J Cancer Prev 22: 328-34, 2013.
38. Berrington de GA, Yun JE, Lee SY, Klein AP and Jee SH: Pancreatic cancer and factors associated with the insulin resistance syndrome in the Korean cancer prevention study. Cancer Epidemiol Biomarkers Prev 17: 359-64, 2008.
39. Tang J, Sharma R, Lamerato L, Sheehan M, Krajenta R and Gordon SC: Is previous exposure to hepatitis B a risk factor for pancreatic cancer or hepatocellular carcinoma? J Clin Gastroenterol 48: 729-33, 2014.
40. Zhu F, Li HR, Du GN, Chen JH and Cai SR: Chronic hepatitis B virus infection and pancreatic cancer: a case-control study in southern China. Asian Pac J Cancer Prev 12: 1405-8, 2011.
41. Iloeje UH, Yang HI, Jen CL, Su J, Wang LY, You SL, Lu SN and Chen CJ: Risk of pancreatic cancer in chronic hepatitis B virus infection: data from the REVEAL-HBV cohort study. Liver Int 30: 423-9, 2010.
42. Cai B, Liao K, Song XQ, Wei WY, Zhuang Y and Zhang S: Patients with chronically diseased livers have lower incidence of colorectal liver metastases: a meta-analysis. PLoS One 9: e108618, 2014.
43. Alexopoulos CG, Vaslamatzis M and Hatzidimitriou G: Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumours. Br J Cancer 81: 69-74, 1999.
44. Ikeda M: Reactivation of hepatitis B virus in patients receiving chemotherapy. Jpn J Clin Oncol 43: 8-16, 2013.
45. Ling WH, Soe PP, Pang AS and Lee SC: Hepatitis B virus reactivation risk varies with different chemotherapy regimens commonly used in solid tumours. Br J Cancer 108: 1931-5, 2013.
46. Mindikoglu AL, Regev A and Schiff ER: Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention. Clin Gastroenterol Hepatol 4: 1076-81, 2006.
47. Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, Hui P, Leung NW, Zee B and Johnson PJ: Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 62: 299-307, 2000.
48. Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F and Csako G: Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 148: 519-28, 2008.